source
- #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsBoehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE-1…Endpoints · 1mo ago↗ source
- STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drugBoehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.STAT · 1mo ago↗ source
- STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet endingYou're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.